Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Biogen Ma Inc patents (2016 archive)


Recent patent applications related to Biogen Ma Inc. Biogen Ma Inc is listed as an Agent/Assignee. Note: Biogen Ma Inc may have other listings under different names/spellings. We're not affiliated with Biogen Ma Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Biogen Ma Inc-related inventors


Compositions comprising antibodies to lingo or fragments thereof

Endogenous lingo-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous lingo-1 function, such anti-lingo-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. ... Biogen Ma Inc

Method for delivering interferon-beta

The method described herein reduces the amount of aggregating metal released into solutions of interferon-.beta.. . ... Biogen Ma Inc

Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists

This invention relates to methods for promoting neuronal survival and regeneration using lingo-1 antagonists and trkb agonists. Additionally, the invention relates to methods for treating pressure induced optic neuropathies using lingo-1 antagonists. ... Biogen Ma Inc

On-column viral inactivation methods

The present invention is directed to a method of inactivating virus that is present during production of a polypeptide of interest. In particular, the present invention is directed to a method of on-column virus inactivation using a low ph and high salt wash solution that effectively inactivates viruses with minimum recovery loss of the polypeptide.. ... Biogen Ma Inc

Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications

The present invention relates to improved methods in the separation recombinant polypeptides with post-translational modifications from complex mixtures through the use of a cation exchange medium.. . ... Biogen Ma Inc

Infusion pump drive with compression spring

An infusion pump drive and its methods of use are disclosed. In one embodiment, the infusion pump drive may include a transmission component and a spring in line with the transmission component. ... Biogen Ma Inc

Recombinant factor viii proteins

Provided are recombinant factor viii proteins, e.g., human factor viii proteins, in which one or more amino acids in at least one permissive loops or a3 domain are substituted or deleted, or replaced with heterologous moieties, while retaining the procoagulant activity of factor viii.. . ... Biogen Ma Inc

Controlled release dosage form for once daily administration of dimethyl fumarate

A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.. ... Biogen Ma Inc

Population pharmacokinetics tools and uses thereof

The present invention is directed to computer based pharmacokinetics systems, such as. Web-based pharmacokinetics systems, and their use to predict a dose and a dosing interval for a patient in need of a clotting factor therapy.. ... Biogen Ma Inc

Control of protein glycosylation by culture medium supplementation and cell culture process parameters

The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.. ... Biogen Ma Inc

Apparatus and related method to facilitate testing via a computing device

This disclosure relates to a device to mechanically and electrically connect with a touch screen computing device, such as a tablet computer. The device can include a platform that can be moved into and out of physical contact with a surface of a touch screen. ... Biogen Ma Inc

Method for distribution of a drug

A method of providing an anti-vla-4 antibody to a patient.. . ... Biogen Ma Inc

Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality

Methods of improving the efficiency of production of a protein product of interest in mammalian cell culture are presented. In particular, the methods result in an increase in the quantity of a protein product produced, or decreases protein product production time in a manufacturing-scale bioreactor cell culture. ... Biogen Ma Inc

Procoagulant fusion compound

The present invention provides a fusion compound comprising a procoagulant compound and an immunoglobulin constant region or a portion thereof and methods of making and using the fusion compound. The fusion compounds of the present disclosure are useful for the treatment of coagulation disorders, such as hemophilia. ... Biogen Ma Inc

09/22/16 / #20160274125

Anti-vla-4 related assays

Methods and apparatus for assaying the level of analytes in a sample, related to vla-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.. ... Biogen Ma Inc

09/08/16 / #20160259913

Drug delivery dose indicator

Embodiments of the disclosure include a transponder for determining a characteristic of a dose delivery device. The transponder may include a first sensor configured to detect a first parameter of the dose delivery device based on movement of at least one of the dose delivery device or a medicament contained within the dose delivery device, wherein the first sensor is configured to generate a first signal indicative of the first parameter. ... Biogen Ma Inc

09/01/16 / #20160251408

Thrombin cleavable linker with xten and its uses thereof

. . The present invention provides a chimeric molecule comprising a vwf protein fused to a heterologous moiety via a vwf linker. The invention provides an efficient vwf linker that can be cleaved in the presence of thrombin. ... Biogen Ma Inc

09/01/16 / #20160250340

Polymer conjugates of interferon beta-1a and uses

An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.. ... Biogen Ma Inc

08/25/16 / #20160243224

Tweak antagonists for treating lupus nephritis and muscle atrophy

Methods and compositions for treating lupus nephritis and muscle atrophy with anti-tweak antibodies are provided. Methods that include administering therapeutically effective amounts of anti-tweak antibodies to human subjects already receiving a standard treatment for lupus nephritis are also encompassed. ... Biogen Ma Inc

08/18/16 / #20160237399

Control of protein glycosylation by culture medium supplementation and cell culture process parameters

The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.. ... Biogen Ma Inc

08/11/16 / #20160229903

Thrombin cleavable linker

The present invention provides a chimeric molecule comprising a vwf protein fused to a heterologous moiety via a vwf linker. The invention provides an efficient vwf linker that can be cleaved in the presence of thrombin. ... Biogen Ma Inc

08/11/16 / #20160228577

Transgenic animals for in vivo imaging

Compositions, methods and transgenic animals for in vivo detection of ectopically expressed sodium iodide symporter (nis) are provided.. . ... Biogen Ma Inc

08/11/16 / #20160228513

Treatment of melanoma with interferon-beta and ras-raf-mek-erk inhibitor combination therapy

This description relates to the use of a polymer-conjugated interferon-beta as monotherapy or in combination with other cancer therapies.. . ... Biogen Ma Inc

07/28/16 / #20160213745

Use of lingo-4 antagonists in the treatment of conditions involving demyelination

The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a lingo-4 antagonist.. . ... Biogen Ma Inc

06/02/16 / #20160152709

Compositions and methods for treatment of stroke

The invention relates, inter alia, to methods of treating stroke, e.g., ischemic stroke, e.g., acute ischemic stroke, and methods of reducing infarct size and/or other neurological deficits associated with stroke, e.g., ischemic stroke, e.g., acute ischemic stroke, using a vla-4 antagonist such as natalizumab. It was discovered that vla-4 antagonists such as natalizumab can effectively reduce the infarct size and other associated neurological deficits of a stroke, e.g., an ischemic stroke; e.g., an acute ischemic stroke, e.g., when administered within a specified time period after the onset of the stroke. ... Biogen Ma Inc

06/02/16 / #20160151390

Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (pml)

The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a dna virus (e.g., a jc virus or a bk virus). Aspects of the invention are useful to prevent or treat dna virus associated conditions (e.g., pml) in subjects that are immuno-compromised. ... Biogen Ma Inc

05/19/16 / #20160137739

Oncostatin m receptor antigen binding proteins

The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins. E.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. ... Biogen Ma Inc

05/12/16 / #20160131634

Methods of evaluating cell culture additives

The present disclosure shows, unexpectedly, that variations in cell culture performance in large-scale cell culture systems such as, for example, those used in commercial manufacturing processes, in some instances, can be attributed to often subtle variations among shear-protectant additives used during cell culture. Assessing the quality of shear-protective additives using such large-scale systems, however, is inaccurate, time-consuming and costly. ... Biogen Ma Inc

05/12/16 / #20160130361

Anti-factor viii antibodies or uses thereof

The present invention provides anti-fviii antibodies and antigen-binding molecules thereof which specifically bind fviii epitopes. The antibodies and antigen-binding molecules can be used to purify fviii. ... Biogen Ma Inc

05/12/16 / #20160129023

Bicyclic aryl sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the s1p receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at s1p receptors.. ... Biogen Ma Inc

04/28/16 / #20160116483

Method of assessing risk of pml

The invention relates to methods of assessing a patient's risk of developing progressive multifocal leukoencephalopathy (pml).. . ... Biogen Ma Inc

04/28/16 / #20160115540

Prodrugs and drugs

Methods and systems to evaluate a prodrug are provided.. . ... Biogen Ma Inc

04/28/16 / #20160115467

Chimeric fvii-xten molecules and uses thereof

The present invention provides chimeric fvii molecules comprising fvii, an xten polypeptide, and an antibody c and antigen-binding molecules thereof which specifically bind the α and/or β subunits of the non-active form of the gpiib/iiiia receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties, e.g., half-life extending moiety. ... Biogen Ma Inc

04/28/16 / #20160115234

Anti-gpiib/iiia antibodies or uses thereof

The present invention provides antibodies and antigen-binding molecules thereof which specifically bind the α and/or β subunits of the non-active form of the gpiib/iiiia receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties and used, for example, as targeting moieties. ... Biogen Ma Inc

03/24/16 / #20160083468

Compositions comprising antibodies to lingo or fragments thereof

Endogenous lingo-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous lingo-1 function, such anti-lingo-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. ... Biogen Ma Inc

02/18/16 / #20160045570

Biomarkers predictive of therapeutic responsiveness to ifnb and uses thereof

Methods, assays and kits for the identification, assessment and/or treatment of a subject having multiple sclerosis (ms) (e.g., a patient with relapsing-remitting multiple sclerosis (rrms)) are disclosed.. . ... Biogen Ma Inc

02/11/16 / #20160040236

Systems and methods for characterization of multiple sclerosis

Methods and systems to characterize multiple sclerosis in a subject, e.g., in a subject a progressive form of ms are disclosed.. . ... Biogen Ma Inc

02/11/16 / #20160039825

S1p and/or atx modulating agents

Compounds of formula (i), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more sip receptors and/or the activity of autotaxin (atx).. . ... Biogen Ma Inc

02/04/16 / #20160031992

Anti-alpha v beta 6 antibodies and uses thereof

Humanized antibodies and antibody fragments thereof that bind to αvβ6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to treat or prevent αvβ6-mediated diseases such as fibrosis and cancer.. ... Biogen Ma Inc

02/04/16 / #20160030604

Compositions and methods for assessing neuromuscular function

The invention provides compositions and methods for evaluating neuromuscular function in a subject, e.g., a subject at risk for or suffering from a neuromuscular disorder.. . ... Biogen Ma Inc

02/04/16 / #20160029983

Assessment of labeled probes in a subject

Wearable apparatus and method of using same for tracking a labeled probe in a subject are disclosed.. . ... Biogen Ma Inc

01/28/16 / #20160025633

Use of raman spectroscopy to monitor culture medium

In one aspect, the disclosure provides a method of defining a raman signature of a culture component, the method comprising: obtaining a raman spectrum of a culture component in a non-interfering or minimally-interfering solution, identifying peaks in the raman spectrum that are associated with the culture component, obtaining a raman spectrum of a culture medium comprising the culture component, and, removing peaks of the culture component in the raman spectrum of the culture medium that are distorted compared to the peaks identified in the raman spectrum of the culture component in a non-interfering or minimally-interfering solution.. . ... Biogen Ma Inc

01/28/16 / #20160024145

Hydrophobic interaction protein chromatography under no-salt conditions

Various aspects and embodiments of the present disclosure relate to the purification antibodies by hydrophobic interaction chromatography under no-salt conditions.. . ... Biogen Ma Inc

01/21/16 / #20160017042

Anti-alpha v beta 6 antibodies and uses thereof

Humanized antibodies and antibody fragments thereof that bind to αvβ6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to diagnose, treat, and/or prevent αvβ6-mediated diseases such as acute tissue injury, fibrosis, and cancer.. ... Biogen Ma Inc

01/21/16 / #20160017041

Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies

Methods of using antibodies and antibody fragments that specifically bind αvβ5 or β5 to treat or prevent acute kidney injury and/or its sequelae are disclosed.. . ... Biogen Ma Inc

01/14/16 / #20160010063

Arginine inactivation of viruses

The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodiments, inactivation or reduction of viral titers by exposure to arginine is achieved in a neutral (ph˜7) or near neutral (˜ph 6 to ˜ph 8) environment.. ... Biogen Ma Inc

01/07/16 / #20160002743

High resolution melting analysis assay for the detection of viral dna

In one aspect, the disclosure provides methods, kits and compositions for determining the presence of a jc virus mutant in a sample.. . ... Biogen Ma Inc

01/07/16 / #20160002329

Treatment of conditions involving demyelination

The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an sp35 antagonist. Additional methods include methods for inhibiting the binding of the sp35 polypeptide with the erbb2 polypeptide and a method for increasing erbb2 phosphorylation by contacting oligodendrocytes with an effective amount of a composition comprising an sp35 antagonist of the invention. ... Biogen Ma Inc

01/07/16 / #20160002265

Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases

Provided are compounds of formula (i), or pharmaceutically acceptable salts thereof, wherein i.a. Ring a is phenylene or 5- to 6-membered heteroarylene; ring b is phenylene, 5- to 6-membered heterocycloalkylene or 5- to 6-membered heteroarylen; r4 is absent, heteroarylene, arylene, c1-3 alkylene, or r4 and r3 taken together with the nitrogen to which they are bound form a 3- to 7-membered heterocycloalkyl ring; r5 is absent, c(0)nr51, nr52 or 0; r6 is c2-10 alkylene or alkenylene, wherein one or two of the carbon atoms in the alkylene chain is optionally replaced by an 0, s, so, so2 or nr61, and wherein two of the carbon atoms in the alkylene chain are optionally connected by a two or three carbon atom alkylene chain to form a 5- to 7-membered ring; r7 is absent, nr71 or o. ... Biogen Ma Inc

01/07/16 / #20160000888

Factor ix polypeptide formulations

The present invention provides formulations comprising a factor ix-fcrn binding partner (fixfbp) polypeptide, and methods of administering fixfbp.. . ... Biogen Ma Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Biogen Ma Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Biogen Ma Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###